Download PDF
Aktuelle Dermatologie 2019; 45(11): 552-556
DOI: 10.1055/a-0966-4945
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Die Dermatologie in der BG Klinik Falkenstein

Dermatology in BG Klinik Falkenstein
M. Gina
Berufsgenossenschaftliche Klinik für Berufskrankheiten Falkenstein, Abteilung für Berufsdermatologie
› Author Affiliations
Further Information

Publication History

Publication Date:
13 November 2019 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Das stationäre Heilverfahren im Rahmen der tertiären Individualprävention wurde für schwere, therapieresistente Berufsdermatosen entwickelt, wenn das ambulante Management nicht ausreichend ist. Das Heilverfahren ist mittlerweile gut etabliert und wird in 5 Kliniken deutschlandweit angeboten. Die BG Klinik Falkenstein liegt im Herzen des Vogtlandes umgegeben von einem Naturschutzgebiet. Hier können durch Schulungen, multidisziplinäre Diagnostik und Behandlung sowie Optimierung der Präventionsmaßnahmen eine Steigerung der Motivation und bei ca. ⅔ der Betroffenen ein weiterer Berufsverbleib ermöglicht werden.

Abstract

Outpatient management of occupational skin diseases may be difficult. A tertiary individual prevention programme is offered to patients with severe occupational skin diseases in Germany. This concept is currently well established in five specialised dermatological centres. One of them is the BG Klinik Falkenstein. It is situated in a protected landscape in the middle of Vogtland, Saxony. Due to interdisciplinary diagnostic procedures, dermatological treatment, patient education (health and psychological) about ⅔ of patients are able to continue their occupation.

 

  • Literatur

  • 1 Skudlik C, Weisshaar E, Scheidt R. et al. Multicenter study “Medical-Occupational Rehabilitation Procedure Skin – optimizing and quality assurance of inpatient-management (ROQ)”. J Dtsch Dermatol Ges 2009; 7: 122-126
    PubMedGoogle Scholar
  • 2 Skudlik C, Weisshaar E, Scheidt R. et al. First results from the multicentre study rehabilitation of occupational skin diseases – optimization and quality assurance of inpatient management (ROQ). Contact Dermatitis 2012; 66: 140-147
    CrossrefPubMedGoogle Scholar
  • 3 Weisshaar E, Skudlik C, Scheidt R. et al. Multicentre study ‘rehabilitation of occupational skin diseases – optimization and quality assurance of inpatient management (ROQ)’ – results from 12-month follow-up. Contact Dermatitis 2013; 68: 169-174
    CrossrefPubMedGoogle Scholar
  • 4 Brans R, Skudlik C, Weisshaar E. et al. Multicentre cohort study ‘Rehabilitation of Occupational Skin Diseases – Optimization and Quality Assurance of Inpatient Management (ROQ)’: results from a 3-year follow-up. Contact Dermatitis 2016; 75: 205-212
    CrossrefPubMedGoogle Scholar
  • 5 Diepgen T, Krohn S, Bauer A. et al. Empfehlung zur Begutachtung von arbeitsbedingten Hauterkrankungen und Hautkrebserkrankungen-Bamberger Empfehlung. Dermatologie in Beruf und Umwelt 2016; 64: 89
    CrossrefPubMedGoogle Scholar
  • 6 Brasch J, Becker D, Aberer W. et al. Guideline contact dermatitis: S1-Guidelines of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG. Allergo J Int 2014; 23: 126-138
    CrossrefPubMedGoogle Scholar
  • 7 Frosch PJ, Schnuch A, Uter W. Kontaktdermatitis: ein Leitfaden für die Praxis unter besonderer Berücksichtigung von Berufsdermatosen. Feistle: Dustri-Verlag; 2014
    Google Scholar
  • 8 Johansen JD, Bruze M, Andersen KE. et al. The repeated open application test: suggestions for a scale of evaluation. Contact Dermatitis 1998; 39: 95-96
    CrossrefPubMedGoogle Scholar
  • 9 Brancaccio RR, Alvarez MS. Contact allergy to food. Dermatol Ther 2004; 17: 302-313
    CrossrefPubMedGoogle Scholar
  • 10 Bauer A, Schubert S, Geier J. et al. Type IV contact allergies in the food processing industry: an update. Hautarzt 2018; 69: 443-448
    CrossrefPubMedGoogle Scholar
  • 11 Przybilla B, Ruëff F, Walker A. et al. Diagnose und Therapie der Bienen-und Wespengiftallergie. Allergo J 2011; 20: 318-339
    CrossrefPubMedGoogle Scholar
  • 12 de Weck AL, Sanz ML. Cellular allergen stimulation test (CAST) 2003, a review. J Investig Allergol Clin Immunol 2004; 14: 253-273
    PubMedGoogle Scholar
  • 13 Allmers H, Schmengler J, John SM. Decreasing incidence of occupational contact urticaria caused by natural rubber latex allergy in German health care workers. J Allergy Clin Immunol 2004; 114: 347-351
    CrossrefPubMedGoogle Scholar
  • 14 Vandenplas O, Raulf M. Occupational Latex Allergy: the Current State of Affairs. Curr Allergy Asthma Rep 2017; 17: 14
    CrossrefPubMedGoogle Scholar
  • 15 Wu M, McIntosh J, Liu J. Current prevalence rate of latex allergy: Why it remains a problem?. J Occup Health 2016; 58: 138-144
    CrossrefPubMedGoogle Scholar
  • 16 Diepgen TL, Fartasch M, Hornstein OP. Evaluation and relevance of atopic basic and minor features in patients with atopic dermatitis and in the general population. Acta Derm Venereol Suppl (Stockh) 1989; 144: 50-54
    PubMedGoogle Scholar
  • 17 Schurer NY, Schwanitz HJ. Prevention and regeneration of barrier disturbances in occupational dermatology. J Dtsch Dermatol Ges 2004; 2: 895-904
    CrossrefPubMedGoogle Scholar
  • 18 Diepgen TL, Agner T, Aberer W. et al. Management of chronic hand eczema. Contact Dermatitis 2007; 57: 203-210
    CrossrefPubMedGoogle Scholar
  • 19 Nast A, Augustin M, Boehncke WH. et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris – Update: „Übersicht der Therapieoptionen“ und „Efalizumab“: evidence-based (s3) guideline for the treatment of psoriasis vulgaris – Update: „therapeutic options“ and „efalizumab“. Journal der Deutschen Dermatologischen Gesellschaft 2010; 8: 65-66
    CrossrefPubMedGoogle Scholar
  • 20 Nast A, Spuls P, van der Kraaij G. et al. European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017; 31: 1951-1963
    CrossrefPubMedGoogle Scholar
  • 21 Diepgen TL, Andersen KE, Chosidow O. et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges 2015; 13: e1-22
    PubMedGoogle Scholar
  • 22 Bauer A, Ronsch H, Elsner P. et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev 2018; 4: CD004414
    PubMedGoogle Scholar
  • 23 Wohlrab J. Topical preparations and their use in dermatology. J Dtsch Dermatol Ges 2016; 14: 1061-1070
    PubMedGoogle Scholar
  • 24 Wollenberg A, Barbarot S, Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682
    CrossrefPubMedGoogle Scholar
  • 25 Lindelof B, Sigurgeirsson B, Gabel H. et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143: 513-519
    PubMedGoogle Scholar
  • 26 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
    CrossrefPubMedGoogle Scholar
  • 27 Stege H. Ultraviolet therapy in patients with chronic hand eczema. Hautarzt 2008; 59: 696-702
    CrossrefPubMedGoogle Scholar
  • 28 Molin S, Ruzicka T. Alitretinoin: a new treatment option for chronic refractory hand eczema. Hautarzt 2008; 59: 703-704 706 – 709
    CrossrefPubMedGoogle Scholar
  • 29 Diepgen TL. Chronic hand eczema: epidemiology and therapeutic evidence. Hautarzt 2008; 59: 683-684 686 – 689
    CrossrefPubMedGoogle Scholar
  • 30 Wollenberg A, Barbarot S, Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878
    CrossrefPubMedGoogle Scholar
  • 31 Lee N, Chipalkatti N, Zancanaro P. et al. A Retrospective Review of Dupilumab for Hand Dermatitis. Dermatology 2019; 235: 187-188
    CrossrefPubMedGoogle Scholar
  • 32 Garzorz-Stark N, Krause L, Lauffer F. et al. A novel molecular disease classifier for psoriasis and eczema. Exp Dermatol 2016; 25: 767-774
    CrossrefPubMedGoogle Scholar
  • 33 Weisshaar E, Gazorz-Stark N, Eyerich K. Ekzem oder Psoriasis? Eine spezielle Herausforderung in der Berufsdermatologie. Dermatologie in Beruf und Umwelt 2018; 66: 113-119
    CrossrefPubMedGoogle Scholar
  • 34 Wehrmann J, Scheewe S, Weyergraf A. et al. S1 Leitlinie 013/083: Stationäre dermatologische Rehabilitation. 5: 2015 Stand 2015
    PubMedGoogle Scholar